Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

Obesity Clinical Trial

— RIALTO  

Official title:

A 12-month Multicentre, Randomised, Double-blind, Placebo-controlled Study With Two Parallel Groups to Assess the Effects of Rimonabant 20 mg in Patients With Abdominal Obesity and Microalbuminuria, With Type 2 Diabetes Mellitus or Dyslipidaemia With or Without Other Cardiometabolic Risk Factors.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00458081
• Other study ID #: RIMON_L_01031
• Secondary ID: EudraCT # : 2006
• Status: Terminated
• Phase: Phase 3
• First received: April 6, 2007
• Last updated: December 9, 2010
• Start date: March 2007
• Est. completion date: January 2009

Study information

• Verified date: December 2010
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

Primary objective:

• To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.

Secondary objectives:

• Percentage of patients in both arms of the study whose levels of microalbuminuria decrease, stabilise, increase towards macroalbuminuria or are unchanged after 12 months of treatment with rimonabant or placebo.

• To assess the effect of treatment with rimonabant 20 mg versus placebo over a 12 month period on:

• Weight and waist circumference.

• Glycaemia profile: fasting glycaemia, fasting insulinaemia and HbA1c.

• Lipid and lipoprotein profile: triglycerides, total cholesterol, HDL-C, LDL-C, apolipoproteins A1 and B.

• Inflammatory markers

• Adipocytokines.

• Blood pressure.

• Glomerular filtration rate.

• To assess the quality of life by means of questionnaire filled in.

• Safety parameters

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 174
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Body Mass Index > 27 kg/m2 and < 40 kg/m2.

• Waist circumference > 102 cm in men and > 88 cm in women.

• Microalbuminuria >= 20 mg/g creatinine and < 300 mg/g creatinine in at least two of three morning urine samples taken on 3 separate days prior to the baseline visit.

• Type 2 diabetes and/or dyslipidaemia.

Exclusion Criteria:

• Breastfeeding or pregnant women or who expect to become pregnant.

• Non-use of approved methods of contraception in women of child-bearing potential.

• History of very low calorie diet in the 3 months prior to the screening visit (<1200 kcal/day).

• Change in weight > 5 kg in the 3 months prior to the screening visit.

• History of surgery for weight loss (such as vertical banded gastroplasty, gastric by-pass, etc.)

• History of bulimia or anorexia nervosa according to DSM-IV definition.

• Any clinically significant endocrine disorder, in the opinion of the investigator, especially known alterations in the blood concentration of TSH and free T4.

• Type 1 Diabetes

• Triglyceridaemia > 400 mg/dl (4.52 mmol/l)

• Severe renal dysfunction

• Chronic Hepatitis or clinically known significant liver disease or ALT and/or AST > 3x the upper limit of the normal range at the screening visit.

• Hypertension at the screening visit.

• Presence of any condition (medical, including clinically significant abnormal laboratory tests, physiological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study.

• History of abuse of alcohol or other substances (except smoking).

• Hypersensitivity or intolerance to the active ingredient or any of the excipients, such as lactose.

Concomitant medication prior to the screening visit

• Administration of any treatment undergoing clinical investigation (drug or medical device) in the 30 days prior to the screening visit.

• Previous treatment with rimonabant.

• Administration of any of the following products in the 3 months prior to the screening visit

• Anti-obesity drugs (such as, sibutramine or orlistat).

• Other weight loss drugs (phentermine,amphetamines).

• Weight loss herbal preparations.

• Nicotinic acid, fibrates, bile acid sequestrants or Omega 3 drugs (e.g. Omacor).

• Prolonged use (more than a week) of systemic corticosteroids or neuroleptics

• Antidepressants (including bupropion)

• Insulin, thiazolidinediones, a-glucosidase inhibitors, meglitinides or any group of antidiabetic drugs (except combination of biguanides and sulfonylureas)

• In type 2 diabetes patients, start of or change in treatment with sulfonylureas and/or metformin, in the 4 weeks prior to the screening visit.

• Start of or change in treatment with antihypertensive drugs in the 12 weeks prior to the screening visit.

• Start of or change in treatment with statins and/or ezetimibe in the 8 weeks prior to the screening visit.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Albuminuria
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Dyslipidemia
• Dyslipidemias
• Microalbuminuria
• Obesity

Intervention

Drug:
• Rimonabant
20 mg once per day + slightly reduced calorie diet
• Placebo
placebo once per day + slightly reduced calorie diet

Locations

Country	Name	City	State
Spain	Sanofi-Aventis Administrative Office	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative change in the microalbuminuria level.		between baseline visit and Month 12	No
Secondary	Percentage of patients whose albuminuria levels decrease, stabilise, are progressing towards macroalbuminuria, are unaltered.		between baseline visit and Month 12	No
Secondary	Relative change and absolute change of Weight, Waist circumference, Body mass index (weight and height), Specific lipid parameters, Glycaemia control parameters, Proinflammatory markers, Adipocytokines, Glomerular filtration rate, Blood pressure		between baseline visit and Month 12	No
Secondary	Evaluation of the Quality of Life (questionnaire IWQOL).		at baseline visit and at 3, 6 and 12 months visit	No
Secondary	Safety (including neuropsychiatric events) and Laboratory assessments.		at each visit and at baseline, 3, 6 and 12 month visits	Yes